Drug
Pexidartinib clinical trials
Also written PLX3397.
- studies test it
- 29
- open now
- 2
- in phase 3
- 2
- first study started
- 2009
Keep track of what changes. Save the pexidartinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
- PLX3397
- 23
Studies by the year they started
29 studies that test it; most in 2015 (7)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 2 |
| 2015 | 7 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 18
- Phase 2
- 12
- Phase 3
- 2
- Phase 4
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 8
Daiichi Sankyo (15) · Daiichi Sankyo Co., Ltd. (4) · Cogent Biosciences, Inc. (1) · Centre Leon Berard (1) · The Christie NHS Foundation Trust (1) · Memorial Sloan Kettering Cancer Center (1) · Barbara Ann Karmanos Cancer Institute (1) · Hope Rugo, MD (1)
Often tested with
Tested in the same studies.
Durvalumab (2) · Paclitaxel (2) · Pembrolizumab (2) · Sunitinib (1) · Binimetinib (1) · Antiandrogen Therapy (1) · Eribulin (1) · Temozolomide (1)
Studies
Open first, then newest update. How each study uses pexidartinib is read from its arms, and is right about nine times in ten.
Testing it · 29
- Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...RecruitingPhase 1National Cancer Institute (NCI)NCT02390752Written as TURALIO(R)
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Written as PLX3397
- A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCTActive, not recruitingPhase 3Daiichi Sankyo Co., Ltd.NCT04488822Written as Pexidartinib
- A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in JapanCompletedPhase 2Daiichi Sankyo Co., Ltd.NCT04703322Written as Pexidartinib
- A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated MelanomaCompletedNot applicableDaiichi Sankyo Co., Ltd.NCT02975700Written as PLX3397
- PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath TumorsTerminatedPhase 1/2Gulam ManjiNCT02584647Written as PLX3397
- CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid TumorsCompletedPhase 1/2Cogent Biosciences, Inc.NCT02401815Written as Pexidartinib
- Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With PexidartinibCompletedPhase 4Daiichi SankyoNCT04526704Written as Pexidartinib
- Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)CompletedPhase 3Daiichi SankyoNCT02371369Written as Pexidartinib
- Study of Pexidartinib in Asian Subjects With Advanced Solid TumorsCompletedPhase 1Daiichi Sankyo Co., Ltd.NCT02734433Written as Pexidartinib
- Safety Study of PLX108-01 in Patients With Solid TumorsCompletedPhase 1Daiichi SankyoNCT01004861Written as PLX3397
- Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal CancersCompletedPhase 1Centre Leon BerardNCT02777710Written as Pexidartinib
- PLX3397 KIT in Acral aNd mucOsal MelanomaCompletedPhase 2The Christie NHS Foundation TrustNCT02071940Written as PLX3397
- Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy ParticipantsCompletedEarly Phase 1Daiichi SankyoNCT04223635Written as Pexidartinib
- Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)CompletedPhase 1Daiichi SankyoNCT03291288Written as Pexidartinib
- A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)CompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT03158103Written as Pexidartinib
- PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate CancerCompletedPhase 1Barbara Ann Karmanos Cancer InstituteNCT02472275Written as Multitargeted Tyrosine Kinase Inhibitor PLX3397
- Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast CancerCompletedPhase 1/2Hope Rugo, MDNCT01596751Written as PLX3397
- Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid TumorsCompletedPhase 1Daiichi SankyoNCT01525602Written as PLX3397
- Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin LymphomaCompletedPhase 2Daiichi SankyoNCT01217229Written as PLX3397
Codes
What other systems call pexidartinib · ClinicalTrials.gg INT000290
- MeSH (NLM) C000600259pexidartinibOne source NLM
- UNII (FDA) 6783M2LV5XPEXIDARTINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2183102One source FDA
- Wikidata Q25100640pexidartinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C88303PexidartinibOne source FDA
- DrugBank DB12978One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000600259 | pexidartinib | One source NLM |
| UNII (FDA) | 6783M2LV5X | PEXIDARTINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2183102 | — | One source FDA |
| Wikidata | Q25100640 | pexidartinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C88303 | Pexidartinib | One source FDA |
| DrugBank | DB12978 | — | One source Wikidata |
Also registered as pexidartinib hydrochloride (UNII YS6WAI3XN7 · RxNorm 2183103).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.